



January 17th 2024

Company name: FINDEX Inc.
Name of representative: Teruo Aibara, President & CEO
(Securities code: 3649; PRIME Market)
Inquiries: Takashi Murakami, Finance &
Investor Relations, Business Strategy
(Telephone: +81-3-6271-8958)

Notice of Preliminary Results on Product Implementations

Following are the preliminary results of product implementations by Findex Inc. as of December 31, 2023.

(As of December 31, 2023)

Product Name	Number of Users			
	University Hospitals	Other General Hospitals	Clinics and Others	Non-Medical Organizations
Claio Data Management Software	93 [+0]	437 [+5]	990 [+36]	—
DocuMaker Document Management Software for Medical Institutions	37 [+0]	131 [+3]	467 [+33]	—
C-Scan Software for Document Digitalization and Management	32 [+0]	118 [+2]	21 [+2]	—
PDI+ MoveBy Reference Information Management Software	27 [+0]	55 [+1]	8 [+0]	—
MapleNote Perinatal Information System	21 [+1]	49 [+1]	6 [+0]	—
REMORA Electronic Medical Record	—	15 [+1]	853 [+27]	—
PiCIs Cloud service for Medical Institutions	3 [+0]	0 [+0]	—	—
DocuMaker Office Document & Public Document Management/e-Approval	3 [+0]	3 [+0]	—	26 [+1]
GAP/GAP-screener Gaze Analyzing Perimeter				95Units [+48]

1. Figures in [] indicate the increase or decrease from the previous announcement. For newly listed products, figures shown are the changes from the actual results as of June 30, 2022, as are those of other products.
2. Progress Note System C-Note and Nystagmus Examination Support System C-Nys are included in Claio in the above implementation results as options for Claio (they are not counted in duplicate).
3. GAP/GAP-screener are counted in terms of the number of units sold.
4. In order to provide preliminary figures on products that will serve as indicators of future business activities, changes have been made to the list of the products above.
5. PiCIs counts the number of installations on a product basis, which may result in multiple counts for the same users.

Note: This is a translation of the document originally prepared in Japanese for reference purpose only. In the event of any discrepancies in words, figures or the like between this document and the original, the original Japanese version shall govern.